Started compounded sema March 2024 at 241 lbs, seven years after my gastric bypass, four years after I hit my low of 168 and then slowly undid it with a stretched pouch and a Chipotle habit. Switched to brand Zepbound 7.5 last August when insurance finally came through. I’m 197 today. Goal is 185 and staying there, not 130, not whatever number would make a good before/after post. The part I didn’t see coming was the labs. My A1c at 241 was 5.8. At 312 lbs before surgery in 2017, it was 5.9. The bypass kept me from sliding into prediabetic territory even through the full regain, which I didn’t appreciate until I started comparing the panels side by side. Now it’s 5.1. That’s not nothing. The thing that’s genuinely weird, and I haven’t seen this discussed much: my LDL right now is lower than it was at my 168 lb low in 2019. At my lowest weight I was eating in terror, small amounts of whatever fit, not remotely intentional about fat quality. Now I’m eating 90+ grams of protein, much less volume overall because tirz has basically restored my old post-op restriction, and the lipid panel reflects that. Bypass changes how you absorb long-chain fats permanently. When regain happens and you start eating like a normal person again, the lipids drift in a specific way that doesn’t track a standard obesity model. What I’m seeing now isn’t just “weight loss improved cholesterol.” It’s something the surgery set up and Zepbound finished. Also, my B12 and iron are stable. Still doing sublingual B12 and separate iron supplement every day, same as I have since 2017. I’m bringing this up specifically because I keep seeing post-op people say the GLP-1 has them eating so little they stopped their bariatric vitamins. Please don’t. Absorption issues don’t fix themselves when appetite drops. They get worse.
the case for bypass-specific lipid effects is real, Roux-en-Y does alter bile acid cycling and long-chain fat absorption in ways that don’t reverse, so I’m not dismissing the mechanism. but “what I’m seeing now isn’t just weight loss improved cholesterol, it’s something the surgery set up and Zepbound finished” is doing a lot of work without controlling for the obvious confounder you named yourself: at 168 lbs you were eating “in terror, small amounts of whatever fit, not remotely intentional about fat quality,” and now you’re deliberate about 90g protein and presumably more thoughtful about fat sources too. that dietary composition change alone would move LDL in most people, bypass or not, and you can’t cleanly separate it from any absorption synergy you’re theorizing. the n=1 framing is fine, I just think the mechanism attribution is getting ahead of the data you actually have access to. the vitamin point is solid and worth repeating louder, that part doesn’t need a caveat.
the confounder point is fair, and I can’t rule it out, but the thing that makes me less sure dietary composition explains all of it: my LDL at 168 was actually higher than my LDL at 241, which runs backward from what a simple dietary quality story would predict. at 241 I was eating more volume, more fat overall, less intentional protein, and the number was still lower than my lowest-weight labs. that’s what made me think the bypass absorption piece was doing something specific. not claiming I’ve isolated the mechanism, just noting the directionality doesn’t line up cleanly with “better food choices at lower weight.” you’re right that n=1 with confounders isn’t a conclusion. it’s a pattern worth tracking, which is why I started flagging the labs across timepoints instead of just noting the direction.
The directionality inversion is the part worth holding onto, bc the standard model for post-bariatric lipid recovery assumes weight and dietary composition improve in parallel, and your case separates those variables in a way most retrospective bypass data doesn’t. One mechanism worth noting: RYGB permanently reduces bile acid reabsorption in the terminal ileum, which upregulates hepatic bile acid synthesis from cholesterol and pulls LDL-C down through roughly the same pathway cholestyramine exploits. If that effect was more active during the regain period, driven partly by altered transit and gut architecture, it could explain why your LDL at 241 was paradoxically lower than at 168 without requiring a purely dietary story. What I’d actually want to see from your panels is whether particle size or ApoB was measured at any of those timepoints, bc the bypass-bile acid interaction tends to preferentially reduce small dense LDL, and standard LDL-C doesn’t capture that shift. The summary number can look worse or better than the actual atherogenic picture depending on which fraction changed.